Background Several randomised controlled trials (RCTs) have investigated the usefulness of pituitary block with gonadotrophinreleasing hormone (GnRH) antagonists during intrauterine insemination (IUI) cycles, with conflicting results.
Introduction
Intrauterine insemination (IUI) with controlled ovarian stimulation is the treatment of first choice for subfertile couples due to low costs, minimal invasiveness and requirement of minimal clinical surveillance. [1] [2] [3] The rationale is to increase the natural chances of conceiving by obtaining two or three dominant follicles and performing IUI after multiple ovulation triggering. 4 Different strategies have been proposed to improve the outcome of IUI-stimulated cycles, including endometrial scratching, 5 various ovarian stimulation protocols 6, 7 and pituitary block with gonadotrophin-releasing hormone (GnRH) antagonists (GnRH-ant). 4 These antagonists are synthetic analogues of GnRH that exert a competitive block of GnRH receptors in the anterior pituitary gland. [8] [9] [10] The introduction of GnRH-ant during IUI-stimulated cycles may prevent spontaneous ovulation and premature luteinisation, and may improve clinical pregnancy rate. 11, 12 However, since their first use in 2001, 13 the effectiveness of this strategy remains a subject of debate.
Hence, the aim of the present systematic review was to evaluate the effects of GnRH-ant administration in women undergoing IUI-stimulated cycles.
Methods

Study design
This is a systematic review and meta-analysis of randomised controlled trials (RCTs) evaluating the effectiveness of GnRH-ant use in IUI cycles. The study protocol was registered in PROSPERO before the start of the literature search (CRD42017081201). The review was written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 14 
Search strategy
Electronic databases (Medline, Scopus, Embase, Sciencedirect, the Cochrane library, Clinicaltrials.gov, Cochrane Cen- 
Study selection and data extraction
Titles and abstracts were independently screened by two authors (AV, GS). The same authors independently assessed studies for inclusion and extracted data about study features (design, country and time of the study), populations (participant number and characteristics), type of intervention, ovarian stimulation cycles (drugs, timing of ovulation induction) and IUI outcomes. A manual search of references of included studies was also performed to avoid missing relevant data. The results were compared, and any disagreement was resolved by consensus.
Risk of bias
Two authors (AV, MN) independently assessed the methodological quality of included studies by using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. Seven specific domains related to risk of bias were assessed: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective data reporting; other bias. Authors' judgements were expressed as 'low risk', 'high risk' or 'unclear risk' of bias. For the estimation of 'selective data reporting', we evaluated study protocols, when available. If not available, studies were judged at unclear risk of bias. Results were compared and disagreements were resolved by consensus.
Statistical analysis
Data analysis was performed by two authors (AV, GS) using REVIEW MANAGER Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK). All analyses were carried out with an intention-to-treat approach (number of events per woman randomised), using the random effects model of DerSimonian and Laird (assuming that the data being analysed were drawn from a hierarchy of different populations). Dichotomous variables were analysed using the odds ratio (OR) with a 95% CI. Continuous variables were compared using the means and standard deviations of outcome measures and expressed as mean differences (MD) among groups (95% CI). Significance level was set at P < 0.05. Heterogeneity was measured using I-squared (Higgins I 2 ). A subgroup analysis was also performed to evaluate the specific influence of different interventions (cetrorelix, ganirelix), intervention schemes (fixed, flexible) and populations [polycystic ovarian syndrome (PCOS), non-PCOS] on pooled results. In addition, we performed a sensitivity analysis by serially excluding each study and different study subgroups (according to the methodological quality judgement) from the pooled analysis.
Publication bias was assessed (for the primary outcomes) with the use of funnel plot (when at least ten studies were included in data analysis, according to Cochrane Handbook Recommendations) and statistically by using Begg's and Egger's tests.
Grading of evidence
Two authors (AV and MN) independently evaluated the quality of evidence for the primary outcomes using GRADE (Grading of Recommendations Assessment Development and Evaluation working group) methodology. 15 The GRADE criteria allow the assessment of a body of evidence on the basis of study design, risk of bias, indirectness, inconsistency, imprecision, large effect size, plausible confounding, dose-response gradient and publication bias. Dose-response gradient was not evaluated because the intervention had standard dose. Disagreements between reviewers were resolved by consensus.
Results
Study selection
In all, 23 studies were assessed for eligibility. Eight studies were subsequently excluded after the examination of full-text: two studies were not RCT. 16, 17 Ragni et al. 13 aimed to evaluate the luteal phase profile in women undergoing IUI-stimulated cycles with/without GnRH-ant. Two studies evaluated the effectiveness of different stimulation protocols in women receiving gonadotrophins plus GnRH-ant before IUI. 18, 19 Two additional studies investigated the benefits of GnRH-ant use to avoid IUI on weekends. 20, 21 In Nada et al., 22 the intervention (GnRH-ant) group and control (GnRH-ant-free) group received different stimulation drugs (respectively gonadotropins and clomiphene citrate). Finally, 15 trials 4, 11, 12, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were included in the meta-analysis ( Figure S1 ).
Included studies
The 15 trials included 3253 IUI cycles and 2345 participants. A total of 1610 IUI cycles were assigned to the intervention group and 1643 to the control group. One study 34 involved three study groups, of which two received the intervention with different timing. Two were placebo-controlled trials. 4, 30 Study characteristics are summarised in the (Table S1 ).
Participants
The majority of the trials included women with unexplained infertility, mild endometriosis (stage I-II) and normal semen analysis/mild male factor. Two studies 12, 25 included also women with PCOS, and two additional studies 29, 34 involved only women with PCOS. In seven studies 4,23-28 participants had no history of previous assisted reproductive treatments, in one study 29 women had three or more previous IUI failures and in another study 30 women had no more than three previous IUI failures. In two studies women had history of one 34 or two 31 previous ovarian stimulation cycles with clomiphene citrate. In the remaining studies 11, 12, 32, 33 previous assisted reproductive treatments attempts were not specified.
IUI cycles
In nine trials, 11, 12, 23, [25] [26] [27] 30, 31, 33 women underwent a single IUI-stimulated cycle, whereas in other studies they underwent up to three 4, 29, 34 or four 24, 28, 32 cycles. Most studies used recombinant follicle-stimulating hormone daily (50-150 IU starting dose) for ovarian stimulation, starting from day 2-4, whereas Kamath et al. 12 administered human menopausal gonadotrophin 75 IU daily (from day 3). Two other studies used the combination of letrozole (5 mg daily from day 3 to 7) plus recombinant follicle-stimulating hormone (150 UI on days 4, 6, 8 and then daily until ovulation induction) 33 or clomiphene citrate (100 mg daily from day 3 to 7) plus human menopausal gonadotrophin (75/150 UI from day 8). 23 Ovulation induction was triggered with 5000-10 000 UI of urinary human chorionic gonadotrophin (hCG) in most studies, except for four 4, 25, 29, 33, 34 (which used recombinant hCG, 250 lg). Recombinant/urinary hCG was administered when at least one follicle (but no more than three) was ≥ 17-20 mm (in mean diameter) at transvaginal ultrasound scan. A single IUI (30- 28 and one group in the study by Stadtmauer et al., 34 where GnRH-ant was started respectively on day 1 or 6 of ovarian stimulation). GnRH-ant was started when at least one follicle ≥ 13 mm, 25 in mean diameter was observed at transvaginal ultrasound scan and continued until ovulation induction.
Assessment of the risk of study BIAS Random sequence generation: All studies but one 24 used adequate method of random sequence generation (computer randomisation or random number tables). Allocation concealment: Seven studies 11,23-26,29-31 did not provide information about the method of allocation, so were judged at unclear risk of bias. Remaining studies were at low risk of bias. Blinding of participants and personnel: All studies but two 4, 30 were not blinded for participants and personnel, so were judged at high risk of bias. Blinding of outcome assessment: Three studies 4,28,30 were assessor-blinded, the remaining were at high risk of bias. Incomplete outcome data: All studies but four 23, 25, 31, 33 were judged at low risk of bias. Two studies 25, 33 were judged at unclear risk of bias as the missing data were not about primary outcomes, while two other studies 23, 31 were considered at high risk of bias due to missing relevant data about primary outcomes. Selective data reporting: All studies were judged at unclear risk of selective data reporting due to absence of recorded study protocol, except for the study by Cantineau et al. 4 Other bias: Three studies 23, 24, 31 were judged at high risk of other bias due to missing information about study methodology and/or patient characteristics. Lambalk et al. 30 was judged at unclear risk of bias because luteal phase support was variable according to preference of clinicians. Another study 25 was judged at unclear risk of bias because it was published as a short communication (Figure S2) .
Effects of intervention
Primary outcomes Analysis of 1964 IUI cycles from seven studies 4, 11, 27, 29, 30, 34 did not show any difference in OPR/LBR between groups (OR 1.14, 95% CI 0.82-1.57, I 2 = 31%, P = 0.44) ( Figure 1A) . Similarly, the analysis of 3192 IUI cycles did not show any advantage from GnRH-ant in terms of CPR (OR 1.28, 95% CI 0.97-1.69, I 2 = 39%, P = 0.08) ( Figure 1B and Video S1).
Secondary outcomes
Significantly lower risks of premature luteinisation (OR 4.39, 95% CI 2.73-7.05, I 2 = 0%, P > 0.00001) ( Figure 2A ) and premature LH rise (OR 3.98, 95% CI 2.53-6.26, I 2 = 28%) ( Figure 2B ) were observed in women receiving intervention, in addition to lower cycle cancellation due to spontaneous ovulation (OR 2.40, 95% CI 1.12-5.15, I 2 = 1%). In contrast, endometrial thickness was found to be lower in the GnRH-ant group in comparison to controls (MD = -0.39; 95% CI -0.70 to -0.08], I 2 = 40%). No difference was observed in terms of miscarriage rate (OR 1.11, 95% CI 0.65-1.89, I 2 = 0%, P = 0.71), multiple pregnancies (OR 1.49, 95% CI 0.82-2.70, I 2 = 0%), preovulatory follicles (MD = -0.07; 95% CI -0.34 to 0.48, I 2 = 97%) and total gonadotrophin dose (MD = -26.51; 95% CI -22.85 to 75.86, I 2 = 84%) among groups. Similarly, no substantial difference in OHSS risk and cancelled cycles due to poor response/hyper-response was observed.
Subgroup analysis and sensitivity analysis
Subgroup analysis according to type of intervention (cetrorelix versus ganirelix), intervention scheme (fixed versus flexible) and type of patients (PCOS versus non-PCOS) showed no statistical difference among subgroups (Figure 1A,B) .
The serial exclusion of each study or specific study subgroups according to authors' quality judgement (studies at low risk of bias in at least four domains) did not provide substantial changes to pooled results.
Publication bias and quality of evidence
No publication bias was found for the outcome OPR/LBR (Begg's test: P = 0.05; Egger's test: P = 0.07). Similarly, the visual inspection of funnel plot, Begg's (P = 0.50) and Egger's test (P = 0.82) did not show the presence of publication BIAS for the outcome CPR ( Figure S3 ).
The quality of evidence for OPR/LBR and CPR was judged as low due to concerns about the overall methodological quality of included studies, moderate inconsistency and small number of events included (Table 1) .
Discussion
In spite of recent insights about endometrial-factor infertility, [35] [36] [37] the introduction of novel targeted drugs [38] [39] [40] and individualised ovarian stimulation protocols, 41 ,42 the success rate of IUI is still suboptimal. 12, 43, 44 Recently, several RCTs have investigated the effectiveness of pituitary block with GnRH-ant during controlled ovarian stimulation and IUI, with controversial results. Our study goal was to summarise the available evidence on this topic.
Main findings
The present meta-analysis, from 15 RCTs, included a total number of 3253 IUI cycles and 2345 women. We found that GnRH-ant use did not improve OPR/LBR and CPR in women undergoing IUI stimulated cycles (P = ns). Nevertheless, GnRH-ant were effective in reducing the risk Figure 2 . Gonadotrophin-releasing hormone antagonist effects on premature luteinisation (A), and premature luteinising hormone rise (B).
of premature luteinisation (P > 0.00001), premature LH rise (P > 0.00001) and spontaneous ovulation (P = 0.02). In contrast, GnRH-ant use correlated with lower endometrial thickness values at the time of ovulation induction (P = 0.02). No difference was observed in terms of miscarriage rate, multiple pregnancies, preovulatory follicles, total gonadotrophin dose, OHSS and cancelled cycles due to hypo-/hyper-response between groups.
A review by Luo et al. 45 investigated the effects of GnRHant on IUI outcomes. The authors found that GnRH-ant were effective in improving CPR and reducing the risk of premature luteinisation, but they did not evaluate the other outcomes included in the present review (i.e. ongoing pregnancy/live birth rate). Moreover, since the study by Luo et al., new RCTs 23,24,31 have been published.
Strengths and limitations
The present meta-analysis, to our knowledge, is the largest and most comprehensive on this issue. Strict inclusion criteria and rigorous methodology represent further points of strength of our study. In addition, sensitivity and subgroup analyses did not produce statistical changes to our results, confirming their consistency.
The main limitations of our study are inherent to the limitations of the included studies. Different outcomes were calculated by pooling the results of a small number of studies and patients (i.e. OPR/LBR). Moreover, a certain heterogeneity between studies in terms of women's characteristics, timing of intervention, ovarian stimulation protocols, IUI techniques and luteal phase support should be taken into account in the interpretation of our findings.
Interpretation
Premature luteinisation and spontaneous ovulation are considered major limiting factors for success with IUI. 25, 26, 29 In the present meta-analysis, we found a large effect of GnRH-ant (introduced when the leading follicle is about 13-14 mm in mean diameter) in the prevention of premature luteinisation (OR 4.95, 95% CI 3.12-7.87). Nevertheless, such an effect was not correlated with any advantage in terms of OPR/LBR and CPR, in line with the results of the study with the greatest weight 4 (according to the authors' quality judgement). We may speculate but it is still not clear how much earlier, before ovulation triggering, the occurrence of LH increase can significantly affect IUI success (in terms of OPR/LBR and CPR).
Interestingly, we also found that GnRH-ant administration was correlated with lower risk of cycle cancellation due to spontaneous ovulation (OR 2.40, 95% CI 1.12-5.15). However, among ten studies (including 2398 IUI cycles, of which 236 were cancelled), only 36 cycles were interrupted due to spontaneous ovulation. Therefore, The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). b GRADE Working Group grades of evidence: High certainty (⨁⨁⨁⨁), we are very confident that the true effect lies close to that of the estimate of the effect; Moderate certainty (⨁⨁⨁s), we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low certainty (⨁⨁ss), our confidence in the effect estimate is limited:; the true effect may be substantially different from the estimate of the effect; Very low certainty (⨁sss), we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. basing on such data and given the considerable costs of GnRH-ant therapy (in Italy: cetrorelix 0.25 mg costs €56.41; ganirelix coses €63.40), this strategy does not appear to be cost-effective for the prevention of spontaneous ovulation in IUI cycles.
Conclusions
In summary, GnRH-ant use did not improve OPR/LBR and CPR in women undergoing IUI stimulated cycles. Given the benefits of GnRH-ant in reducing the risk of premature luteinisation and spontaneous ovulation, further large and well-designed placebo-controlled RCTs are needed.
Disclosure of interests
None declared. Completed disclosure of interests form available to view online as supporting information.
Contribution to authorship
AV designed the study, performed the literature search, defined inclusion criteria and selected studies for inclusion, participated in data extraction, performed the risk of bias assessment, performed statistical analysis and wrote the first draft of the manuscript; GS performed the literature search, selected studies for inclusion, participated in the statistical analysis and the final draft of the manuscript; MN critically revised the manuscript, participated in the assessment of the risk of bias within studies and the grading of evidence; AB structured the manuscript and wrote the final draft of the manuscript; MEC designed the study and critically revised the manuscript; CS participated in the study design and manuscript revision; GB participated in manuscript revision; GBN critically revised the manuscript and participated in the final draft of the manuscript; PL made critical contributions to both data selection and manuscript revision; AA participated in interpretation of results, critically revised the manuscript and participated in the final draft of the manuscript. All authors approved the final manuscript.
Details of ethics approval
Not required.
Funding
Supporting Information
Additional Supporting Information may be found in the online in the Supporting Information section at the end of the article: Figure S1 . PRISMA flow diagram. Figure S2 . Risk of bias graph: the authors' judgment about each risk of bias item presented as percentages across the included studies. Figure S3 . Funnel plot for the outcome clinical pregnancy rate. Table S1 . General features of the studies Video S1. Author insights.&
